Azer-cel (PBCAR0191)
Multiple Sclerosis
Phase 1/2Partnered with TG Therapeutics; Clinical milestone achieved
Key Facts
Indication
Multiple Sclerosis
Phase
Phase 1/2
Status
Partnered with TG Therapeutics; Clinical milestone achieved
Company
About Precision BioSciences
Precision BioSciences leverages its novel ARCUS genome editing platform to create precise gene insertion, knockout, and repair therapies. The company has achieved significant clinical milestones, including FDA Fast Track and Orphan Drug designations for its lead programs, and has demonstrated early clinical safety and antiviral activity for PBGENE-HBV. Its strategy focuses on advancing its wholly-owned pipeline in genetic diseases while maintaining partnerships, such as with TG Therapeutics, to validate its platform in other therapeutic areas.
View full company profileTherapeutic Areas
Other Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Zeposia (ozanimod) | Bristol Myers Squibb | Commercial |
| Copaxone (glatiramer acetate) | Teva Pharmaceutical Industries | Commercial |
| Multiple Sclerosis Portfolio | Biogen | Commercial |
| Kesimpta (ofatumumab) | Genmab | Approved |
| Glatiramer Acetate (Generic Copaxone) | Dr. Reddy's Laboratories | Approved |
| Glatiramer Acetate | Cipla | Commercial |
| Interferon β-1a | Bachem | Commercial |
| KYV-101 | Kyverna Therapeutics | Phase 1/2 |
| CYMS101 | FibroBiologics | Pre-clinical / Limited Clinical |